(Q58434259)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

title

Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

author name string

A du Bois

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

H G Meerpohl

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

F G Kommoss

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

E Fenzl

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

A Pfleiderer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

publication date

1 January 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

21 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

issue

2-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

page(s)

450-457

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

21 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Oncologists' views of cancer patient noncompliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Doxorubicin plus cisplatin in the treatment of apudomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

High-dose metoclopramide and chlorpromazine in the treatment of cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Re

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Combination antiemetics for cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

The neurophysiology of vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy-induced vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Metoclopramide versus metoclopramide and lorazepam. Superiority of combined therapy in the control of cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980075-9

1 reference

7 January 2021

10.1016/S0959-8049(05)80075-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1534250%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

1 reference